Sun Pharma announces FDA tentative approval for generic Cymbalta

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain

📞 Contact Us

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.

Lonza Widens Cell and Gene Therapy Suite with New Products

No New Drug Submissions by the FDA With Shutdown in Place

How to Tell if Your Loved One is Developing an Addiction

The Future of Balding Treatments: What’s New in 2025

Genmab Buys Cancer Biotech Merus in $8B Oncology Deal

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Energy efficiency in pure steam generation: How small adjustments can lead…

Pharmacovigilance Systems Gaining Higher Ground with AI

Overcoming The Pharmaceutical Supply Chain Disruptions

SAE Media Group Unveils Brochure for AI in Drug Discovery 2026…

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt…

Kadans Science Partner secures one of the most significant deals in…

CPHI 2025: BENEO to present galenIQ™ as the granulation binder of…

Kindeva Opens New UK HQ and Manufacturing Site for the Development…

Sun Pharma announces FDA tentative approval for generic Cymbalta

Lonza Widens Cell and Gene Therapy Suite with New Products

No New Drug Submissions by the FDA With Shutdown in Place

How to Tell if Your Loved One is Developing an Addiction

The Future of Balding Treatments: What’s New in 2025

Lonza Widens Cell and Gene Therapy...

No New Drug Submissions by the...

How to Tell if Your Loved...

The Future of Balding Treatments: What’s...

Genmab Buys Cancer Biotech Merus in...

SAE Media Group Unveils Brochure for...

Lonza Widens Cell and Gene Therapy Suite with New Products

No New Drug Submissions by the FDA With Shutdown in Place

How to Tell if Your Loved One is Developing an Addiction

The Future of Balding Treatments: What’s New in 2025

About us

latest updates

System

subscribe us

Resources

Subscribe

Lonza Widens Cell and Gene Therapy Suite with New Products

No New Drug Submissions by the FDA With Shutdown in Place